Vericel Corporation
VCEL · Nasdaq · USD · Market cap $3.0B · 398 employees
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe…
PASS · Titan Ethical · score 70.0Price as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price57.52 USD at the 20 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 16 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.06)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $42.36 to $48.72, base estimate $42.36 (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.06, read 2026-11-20
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Vericel Corporation holds its Markup at $57.52. The statistical read favours the sellers, held for 10 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 10 days |
| Price at the screen | $57.52 |
| Valuation | 90.44 trailing · 61.44 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.06 |
Five Screens: VCEL's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 19.75% | Below 33% | Pass |
| Interest-bearing cash | 12.58% | Below 33% | Pass |
| Receivables | 37.86% | Below 49% | Pass |
| Revenue purity | 2.54% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
Vericel clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when VCEL's ethical verdict changes
Today VCEL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued to fair value, as of 20 Nov 2026: it trades above our $42.36 fair value estimate, 26.50% revenue growth.
USD, 2026-11-20 screen. The price runs 35.8% over base.
Street: 7 covering, consensus Strong Buy. Average target +11%.
Cell Patches Priced Well Beyond Their Reach
Picture a surgeon grafting living cells onto a burned patient or a torn cartilage in an athlete. Vericel supplies those therapies in North America and has lifted revenue 30 percent. Yet the business still clears only a 7 percent profit margin and a matching 7 percent return on equity, leaving little evidence of durable advantage.
We pass. At 54.7 times forward earnings the shares sit 21 percent above our fair value, and the market's strong buy chorus has already baked in flawless execution. An unknown moat in a field where competitors and regulators can shift quickly makes that premium look fragile rather than compelling.
Growth is real and the ethical screen clears, but the numbers show a company that must deliver far more than its current returns to justify today's price. Analysis, not advice.
| Forward P/E | 61.4xexpensive even after accounting for its growth |
| Trailing P/E | 90.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.64 |
| EPS, forward | 0.94 |
| Revenue growth | +26.5%strong top-line growth |
| Profit margin | 10.3%thin but positive margins |
| Return on equity | 9.4%a modest return on shareholder capital |
| FCF yield | 1.69% |
| Debt to equity | 0.24minimal debt: a conservative balance sheet |
| Current ratio | 5.13comfortably covers its short-term bills |
| Beta | 1.06moves a little more than the market |
| Short interest, float | 0.14% |
| 52-week range | 28.95 - 59.75 |
| Market cap | $3.0B |
| Employees | 398 |
VCEL-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from markdown to accumulation since the last review.
The framework has shifted from accumulation to markdown since the last review.
Earnings landed in this window. Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026 Yahoo Finance · 8d ago
- Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy? Yahoo Finance · 11d ago
- Vericel (VCEL) Jumped, What Is Behind The Move? Yahoo Finance · 15d ago
- Vericel Q3 Earnings Call Highlights Yahoo Finance · 15d ago
- Vericel Corp (VCEL) (Q3 2026) Earnings Call Highlights: Record Revenue and Tripled Net Income ... Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $32.92 | +13.6% | · | $1,136 | +13.6% |
| 2 months | $33.70 | +10.9% | · | $1,109 | +10.9% |
| 3 months | $32.11 | +16.4% | · | $1,164 | +16.4% |
| 6 months | $37.39 | 0.0% | · | $1,000 | 0.0% |
| 1 year | $45.70 | -18.2% | · | $818 | -18.2% |
| 2 years | $43.53 | -14.1% | · | $859 | -14.1% |
| 3 years | $34.96 | +6.9% | · | $1,069 | +6.9% |
| 5 years | $57.58 | -35.1% | · | $649 | -35.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever VCEL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.